Trending News

Controversy surrounding additional dose for J&J COVID-19 vaccine recipients

USA: All data and statistics are based on publicly available data at the time of publication. Some information may be out of date. Visit our coronavirus hub and follow our live updates page for the most recent information on the COVID-19 pandemic.

The Johnson & Johnson COVID-19 vaccine, also called Ad26.COV2.S, was developed by Janssen Pharmaceuticals of Johnson & Johnson.

It is a single-dose vaccine, which differentiates it from two-dose COVID-19 vaccines, such as the ones from Pfizer and Moderna.

In early 2021, the Food and Drug Administration (FDA)Trusted Source and, after a recommendation from the European Medicines Agency (EMA), the European Commission issued emergency and conditional authorization for the Johnson & Johnson vaccine for individuals aged 18 years and older. The vaccine has been approved for emergency use in 40 countries.

However, the FDA recommended a pause in the vaccine’s use, as a precautionary measure following a small number of rare blood clot incidents. At the same time, Johnson & Johnson delayed the distribution of the vaccine in Europe while the EMA conducted its own review.

On April 20, the company announced it would resume distribution of its vaccine in the European Union but with a safety warning, after the EMA concluded that the vaccine’s benefits continue to outweigh its risks.

After halting vaccination in the United States a few weeks ago, the FDA and the CDC recently recommendedTrusted Source that vaccinations resume. They noted, however, that women under the age of 50 should be aware of the risk of rare blood clots.

ALSO CHECK:  If you don't prioritize peace, you won't be able to partake in the national cake, warns Nkwanta South MCE.

Moreover, both agencies want women to know that alternative COVID-19 vaccines are available, for which there are currently no reports of rare blood clots.

The World Health Organization (WHO)Trusted Source has stated that, while it continues to monitor the safety responses from regulatory agencies, the vaccine is safe and effective against the severe risks of COVID-19.

How does the vaccine work?

The vaccine is categorized as a viral vector vaccine.

This vaccine form utilizes a different, harmless virus to deliver the genetic instructions for making the SARS-CoV-2 virus’ surface spike protein, which triggers the body’s immune response to produce antibodies. The vaccine does not contain the SARS-CoV-2 virus and cannot cause COVID-19.

The Johnson & Johnson vaccine has a 66% efficacy rate. While this is lower than the efficacy rates of the Pfizer or Moderna vaccines, it should be noted that the clinical trials of the Johnson & Johnson vaccine took place in different contexts — globally in regions where variants were more prevalent, and in the U.S. during a period of significant increase in COVID-19 cases.

The vaccine is around 85% effective at preventing severe disease from COVID-19, including hospitalization and death.

Comments

About the author

Mtn Blogger

Hi, I'm Here to Help you with Music/Video Promotion? Kindly Contact me Via WhatsApp @+233550913164